Blab Business
Merck Group Reports Q2 2026 Profit Decline, Raises Full-Year Guidance
Merck Group’s Q2 2026 earnings, released on August 8, revealed a sharper profit decline than analysts had expected, yet the German science‑and‑technology conglomerate lifted its full‑year outlook.
In the second quarter, the company reported a profit after income tax of €494 million, down 24 % from €655 million a year earlier. Earnings per share fell from €1.50 to €1.13. Net sales edged up to €5.4 billion, a €100 million increase, and the group cited a 4.1 % organic sales growth. Despite the lower profit, Merck upgraded its 2026 guidance and the stock slipped 0.92 % to €145.00 on the Xetra exchange.
Operating performance showed a 9.3 % organic rise in EBITDA pre‑tax, reaching €1.6 billion from €1.5 billion in 2025. Earnings per share before tax climbed to €2.16 from €2.02. The uptick in sales was driven by the Healthcare, Life Sciences and Electronics divisions, with Process Solutions, Rare Diseases and Semiconductor Solutions reporting strong contributions. The operating margin remained roughly unchanged from the prior year.
Merck’s revised guidance for 2026 places net sales between €21.0 billion and €21.8 billion, and EBITDA pre‑tax between €5.9 billion and €6.3 billion. The company clarified that it expects no sales of the drug Mavenclad in the United States after August 2026, a factor that will shape the upper end of the sales corridor. The implied organic growth corridor for net sales is now 1 % to 3 %, and for EBITDA pre‑tax it is 0 % to 3 %. EPS pre‑tax guidance is set at €7.90 to €8.60.
Headquartered in Darmstadt, Germany, Merck Group employs roughly 60,000 people across 66 countries. Its three main business lines—Healthcare, Life Sciences and Electronics—serve markets ranging from pharmaceuticals and diagnostics to semiconductor manufacturing equipment. The 2026 guidance reflects confidence in continued demand for its specialty products and the resilience of its electronics solutions amid global supply‑chain adjustments.
Market participants responded to the earnings release with a modest decline in the group’s share price. On the Xetra exchange the stock closed at €145.00, down 0.92 % from the previous close. The drop followed the company’s announcement of a lower profit margin for the quarter, although the upgraded full‑year outlook has been viewed as a positive signal by some investors.
The 2026 earnings season has seen a mix of pharmaceutical and technology companies report results. Merck’s performance is comparable to peers that have experienced modest profit declines but have upgraded guidance on the back of new product launches and market expansion. The company’s decision to exclude Mavenclad sales from its U.S. forecast reflects a strategic shift in its portfolio management.
Looking ahead, Merck Group will report its third‑quarter results in November 2026. The company’s guidance indicates that it expects to maintain its operating margin and to continue investing in research and development across its three business lines. Investors will also monitor the company’s cash‑flow generation and any regulatory developments that could affect its product portfolio.
In summary, Merck Group’s Q2 2026 results show a decline in profit after tax but an improvement in operating profitability and a stronger outlook for the full year. The company’s guidance upgrade signals confidence in its core businesses, while the exclusion of Mavenclad sales from U.S. forecasts highlights a shift in its product strategy. The market’s modest reaction to the earnings release suggests that investors are weighing the company’s long‑term prospects against the short‑term decline in profitability.
In the second quarter, the company reported a profit after income tax of €494 million, down 24 % from €655 million a year earlier. Earnings per share fell from €1.50 to €1.13. Net sales edged up to €5.4 billion, a €100 million increase, and the group cited a 4.1 % organic sales growth. Despite the lower profit, Merck upgraded its 2026 guidance and the stock slipped 0.92 % to €145.00 on the Xetra exchange.
Operating performance showed a 9.3 % organic rise in EBITDA pre‑tax, reaching €1.6 billion from €1.5 billion in 2025. Earnings per share before tax climbed to €2.16 from €2.02. The uptick in sales was driven by the Healthcare, Life Sciences and Electronics divisions, with Process Solutions, Rare Diseases and Semiconductor Solutions reporting strong contributions. The operating margin remained roughly unchanged from the prior year.
Merck’s revised guidance for 2026 places net sales between €21.0 billion and €21.8 billion, and EBITDA pre‑tax between €5.9 billion and €6.3 billion. The company clarified that it expects no sales of the drug Mavenclad in the United States after August 2026, a factor that will shape the upper end of the sales corridor. The implied organic growth corridor for net sales is now 1 % to 3 %, and for EBITDA pre‑tax it is 0 % to 3 %. EPS pre‑tax guidance is set at €7.90 to €8.60.
Headquartered in Darmstadt, Germany, Merck Group employs roughly 60,000 people across 66 countries. Its three main business lines—Healthcare, Life Sciences and Electronics—serve markets ranging from pharmaceuticals and diagnostics to semiconductor manufacturing equipment. The 2026 guidance reflects confidence in continued demand for its specialty products and the resilience of its electronics solutions amid global supply‑chain adjustments.
Market participants responded to the earnings release with a modest decline in the group’s share price. On the Xetra exchange the stock closed at €145.00, down 0.92 % from the previous close. The drop followed the company’s announcement of a lower profit margin for the quarter, although the upgraded full‑year outlook has been viewed as a positive signal by some investors.
The 2026 earnings season has seen a mix of pharmaceutical and technology companies report results. Merck’s performance is comparable to peers that have experienced modest profit declines but have upgraded guidance on the back of new product launches and market expansion. The company’s decision to exclude Mavenclad sales from its U.S. forecast reflects a strategic shift in its portfolio management.
Looking ahead, Merck Group will report its third‑quarter results in November 2026. The company’s guidance indicates that it expects to maintain its operating margin and to continue investing in research and development across its three business lines. Investors will also monitor the company’s cash‑flow generation and any regulatory developments that could affect its product portfolio.
In summary, Merck Group’s Q2 2026 results show a decline in profit after tax but an improvement in operating profitability and a stronger outlook for the full year. The company’s guidance upgrade signals confidence in its core businesses, while the exclusion of Mavenclad sales from U.S. forecasts highlights a shift in its product strategy. The market’s modest reaction to the earnings release suggests that investors are weighing the company’s long‑term prospects against the short‑term decline in profitability.
